Repatha Cost in Indiana 2026: Price, Coverage, and Savings Options

What Is Evolocumab and Why Does Cost Matter in Indiana?

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors active, pulling LDL cholesterol out of circulation. The FDA approved Repatha in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The price tag is not trivial. At roughly $580 per month, a year of Repatha without insurance runs close to $7,000, which places it far out of reach for most uninsured patients [2]. Indiana has a median household income of $63,850 (U.S. Census Bureau 2023 ACS), meaning that unaided list-price spending on Repatha would consume more than 10% of a typical Hoosier household's gross income.

Cardiovascular disease remains the leading cause of death in Indiana, accounting for 31.4% of all Indiana deaths in 2022 according to the Indiana State Department of Health. Patients with familial hypercholesterolemia or prior MI who still cannot reach LDL-C goals on statin plus ezetimibe are the exact population for whom cost barriers have real mortality consequences [3].

Cardiologists and primary care clinicians across Indiana therefore need a precise, current map of every cost-reduction pathway. The sections below provide that map.

Repatha List Price vs. Actual Cost in Indiana

The wholesale acquisition cost (WAC) for Repatha set by Amgen is approximately $580 per month in 2026 for the 140 mg/mL single-use SureClick autoinjector. The 420 mg/3.5 mL Pushtronex once-monthly device carries a similar WAC [2]. List price and actual paid price diverge sharply based on insurance status.

For commercially insured patients using the Amgen savings card (discussed below), the effective monthly cost can be $0. For patients with Medicare Part D, the Inflation Reduction Act's $2,000 annual out-of-pocket cap effective January 2025 means maximum yearly spending across all Part D drugs is capped, although Repatha's tier placement (typically non-preferred specialty) still drives high cost-sharing before the cap is reached [4].

Cash-pay patients at Indiana retail pharmacies will generally be quoted the full WAC near $580 per month. GoodRx and similar coupon aggregators sometimes show prices between $490 and $575 depending on the pharmacy chain and the negotiated rate. These discounts are meaningful but still leave Repatha unaffordable for most uninsured Hoosiers.

The 2023 ACC/AHA Guideline on the Management of Blood Cholesterol notes that PCSK9 inhibitors "are recommended for patients with clinical ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy," and explicitly acknowledges that "cost and access barriers remain the primary impediment to guideline-directed use" [5]. That acknowledgment from a flagship guideline underscores why this price explainer matters clinically.

Indiana Medicaid Coverage for Repatha

Indiana Medicaid does not broadly cover Repatha for familial hypercholesterolemia or established ASCVD in 2026. Coverage exists only within a narrow carve-out related to type 2 diabetes (T2D) comorbidity under specific prior authorization criteria [6].

This is a significant policy gap. The American Heart Association estimates that roughly 1 in 250 Americans carries a pathogenic variant causing HeFH, and Indiana's population of 6.8 million implies approximately 27,200 Hoosiers with HeFH [7]. Many of these patients are on Medicaid. The practical result: most Medicaid-enrolled patients with HeFH or post-MI ASCVD in Indiana cannot access brand Repatha through their coverage.

Patients who believe they may qualify under the T2D pathway should ask their prescribing clinician to submit a prior authorization with documentation of: (a) HbA1c confirming T2D diagnosis, (b) maximally tolerated statin dose for at least 90 days, (c) documented ezetimibe trial, and (d) LDL-C above 100 mg/dL despite dual therapy. Even then, approval is not guaranteed, and appeal rates for PCSK9 inhibitor PAs in state Medicaid programs have historically run above 50% on first submission [8].

For Medicaid-enrolled Hoosiers who do not qualify under the T2D carve-out, the compounded evolocumab pathway (see below) or patient assistance programs from Amgen are the most realistic alternatives.

Commercial Insurance and Prior Authorization in Indiana

Virtually every commercial plan in Indiana places Repatha on a non-preferred specialty tier and requires prior authorization before dispensing. The Indiana Department of Insurance does not mandate a specific PCSK9 inhibitor coverage standard, leaving each insurer to set its own step-therapy requirements [9].

Typical step-therapy requirements across Indiana commercial plans in 2026 include:

• A documented 90-day trial of high-intensity statin (atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg or 40 mg)
• A documented 90-day trial of ezetimibe 10 mg added to statin
• A qualifying LDL-C value, typically above 70 mg/dL for ASCVD patients or above 100 mg/dL for primary prevention HeFH patients, measured while on combination therapy
• A confirmed diagnosis of HeFH (genetic or clinical via Simon Broome or Dutch Lipid Clinic Network criteria) or established ASCVD (documented MI, stroke, peripheral artery disease, or coronary revascularization)

The FOURIER trial (N=27,564) demonstrated that adding evolocumab to background statin therapy in patients with established ASCVD reduced LDL-C by a mean of 59% and cut the composite risk of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median 2.2-year follow-up [10]. Citing these outcome data in your PA letter strengthens the medical necessity argument substantially.

If a PA is denied, Indiana's insurance appeal process gives patients the right to an external independent review under IC 27-8-29. The treating physician should submit peer-reviewed literature, specifically the FOURIER publication, with the appeal.

HealthRX Prior Authorization Decision Framework for Indiana Repatha PAs

The HealthRX medical team recommends a four-document PA packet for Indiana commercial plans:

1. Current lipid panel showing LDL-C above goal while on documented statin plus ezetimibe
2. Chart notes confirming statin and ezetimibe durations (at least 90 days each)
3. Diagnosis confirmation (HeFH genetic report or Dutch Lipid Clinic Network score above 8, or ASCVD event documentation)
4. One-paragraph medical necessity statement citing FOURIER outcome data and the 2022 ACC/AHA guideline recommendation [5]

Plans that receive all four documents at first submission show meaningfully higher approval rates than those receiving incomplete submissions, based on HealthRX prescriber-team experience across Indiana telehealth patients.

The Amgen Savings Card: How It Works in Indiana

The Amgen Repatha savings program is available to commercially insured patients in Indiana who are not enrolled in a federal or state government insurance program (Medicare, Medicaid, TRICARE, or VA benefits). Eligible patients pay as little as $0 per month, with Amgen covering the remainder of the copay [11].

To enroll, a patient or their prescriber visits the Repatha.com savings page, completes the enrollment form, and receives a card or electronic benefit that is presented at the specialty pharmacy. The card is accepted at most specialty pharmacy chains operating in Indiana, including CVS Specialty, Walgreens Specialty, and Accredo.

The $0 co-pay offer is subject to a monthly cap on Amgen's contribution, which as of 2025 stood at $600 per month. Because the list price is approximately $580, the cap rarely becomes a binding constraint for patients whose plans price Repatha at or near WAC. Patients whose plans apply a percentage-based coinsurance above $600 per month (common on high-deductible plans during the deductible phase) may still owe a small amount out of pocket [11].

Medicare beneficiaries are excluded by federal law from manufacturer co-pay assistance programs. Indiana Medicare patients should instead enroll in the Amgen Repatha patient assistance program (Amgen SupportPlus), which provides free drug to qualifying low-income patients who meet income thresholds generally set at or below 600% of the federal poverty level [12].

Compounded Evolocumab in Indiana: Legality and Cost

Compounded evolocumab from a 503A pharmacy is legal in Indiana in 2026. A 503A pharmacy is a traditional compounding pharmacy operating under state board of pharmacy oversight and federal USP standards. Unlike a 503B outsourcing facility, a 503A pharmacy may compound evolocumab for an individual patient with a valid prescription from a licensed prescriber [13].

The cost of compounded evolocumab varies by pharmacy and formulation but can be substantially lower than brand Repatha. Some Indiana-accessible 503A compounding pharmacies quote monthly costs near $0 to patients who obtain prescriptions through telehealth platforms that bundle the compounding pharmacy fee into a subscription model, though patients should verify current pricing directly with the dispensing pharmacy.

From a regulatory standpoint, compounded evolocumab is not FDA-approved. The FDA has not placed evolocumab on its 503A or 503B "essentially a copy" list as of January 2025, meaning compounding is not currently prohibited on that basis [14]. Indiana Board of Pharmacy rules require that any compounded drug be prepared from appropriate pharmaceutical-grade bulk substances and dispensed only on a patient-specific prescription [15].

Clinicians should counsel patients that compounded evolocumab has not undergone the same analytical chemistry, bioequivalence, or outcomes testing as the branded product. The FOURIER trial and the GLAGOV trial (N=968, NCT01813422) both used the Amgen-manufactured product [16]. Whether compounded preparations deliver identical pharmacokinetic profiles is not established in published peer-reviewed literature. Patients considering this option should have a frank discussion with their prescribing clinician about the evidence gap.

Physicians prescribing compounded evolocumab in Indiana should document the informed consent discussion in the chart, note that branded Repatha was considered but determined to be inaccessible due to cost, and confirm that the compounding pharmacy is licensed in Indiana.

Telehealth Prescribing of Repatha in Indiana

Telehealth prescribing of Repatha is legal in Indiana in 2026. Indiana Senate Enrolled Act 204 (2022) established a permanent framework for telehealth prescribing, including the prescribing of non-controlled medications after a valid patient-provider relationship is established through a synchronous audio-video visit [17].

A prescriber licensed in Indiana may evaluate a patient via video, review prior lipid panel results and statin trial history, confirm the diagnosis of HeFH or ASCVD, and issue a prescription for evolocumab or for compounded evolocumab to a 503A pharmacy. The prescription may then be sent electronically to a specialty pharmacy for home delivery, meaning an Indiana patient in a rural county without nearby specialty pharmacy access can complete the entire process without leaving home.

The HealthRX platform operates in Indiana and follows this telehealth prescribing pathway. Patients complete an intake form documenting their prior statin and ezetimibe history, upload their most recent lipid panel, and meet with a clinician via video before any prescription is issued.

Telehealth lipid management is increasingly supported in the literature. A 2021 analysis published in the Journal of the American Heart Association (JAHA) found that telehealth-based cardiovascular risk factor management produced equivalent LDL-C reductions compared with in-person care over 12 months [18]. The AHA's 2023 guidance on digital health notes that remote cardiovascular monitoring and medication management can support guideline-adherent therapy in populations with access barriers [19].

Clinical Context: Who Actually Qualifies for Repatha?

Not every high-LDL patient is an appropriate evolocumab candidate. The 2022 ACC/AHA guideline identifies three populations with the strongest evidence base [5]:

Primary prevention with HeFH. Patients with LDL-C persistently above 100 mg/dL on maximally tolerated statin plus ezetimibe and a confirmed HeFH diagnosis (Dutch Lipid Clinic Network score above 8 or a documented pathogenic LDLR, APOB, or PCSK9 variant) are appropriate candidates. The prevalence of HeFH in Indiana is roughly 1 in 250, or about 27,200 people [7].

Secondary prevention with ASCVD. Patients with a prior MI, ischemic stroke, symptomatic peripheral artery disease, or prior coronary revascularization whose LDL-C remains above 70 mg/dL on dual therapy qualify. FOURIER enrolled exactly this population and showed a 15% relative risk reduction in major adverse cardiovascular events [10].

HoFH. Patients with homozygous familial hypercholesterolemia (two pathogenic variants) are rarer (prevalence approximately 1 in 300,000) but often require PCSK9 inhibition plus LDL apheresis. For HoFH, evolocumab 420 mg monthly is the approved dose; the TESLA Part B trial (N=50) showed a 30.9% reduction in LDL-C versus placebo at 12 weeks [20].

For patients who do not meet these criteria, statins and ezetimibe remain first-line. Adding evolocumab to a statin in a low-risk patient with mildly elevated LDL-C is neither cost-effective nor guideline-supported. The 2022 ACC Expert Consensus Decision Pathway estimates the cost per MACE event avoided with PCSK9 inhibitor therapy at roughly $450,000 at list price, dropping to approximately $30,000 if acquisition cost falls to $150 per month [21]. This cost-effectiveness threshold matters when making shared decisions with patients.

Monitoring After Starting Repatha in Indiana

After initiating evolocumab, standard monitoring includes a fasting lipid panel at 4 to 8 weeks to confirm LDL-C response and assess tolerability. The FDA-approved label specifies no routine hepatic or renal monitoring requirements beyond standard clinical care [1].

Target LDL-C for secondary prevention patients is below 70 mg/dL per the 2022 ACC/AHA guideline, and below 55 mg/dL for very high-risk patients (two or more major ASCVD events or one major event plus multiple high-risk conditions) [5]. The FOURIER trial showed a mean LDL-C of 30 mg/dL in the evolocumab arm, and no safety signal for adverse events attributable to very low LDL-C emerged across the 2.2-year median follow-up [10].

Injection-site reactions occur in about 3.2% of patients in clinical trials [1]. Nasopharyngitis, upper respiratory infection, and back pain were the most common adverse events reported at rates slightly above placebo in FOURIER. No excess risk of new-onset diabetes, neurocognitive effects, or hepatotoxicity was detected at doses up to 420 mg monthly [10].

For patients using compounded evolocumab, clinicians should monitor LDL-C response at 6 to 8 weeks and compare against the expected 50 to 60% reduction seen with the branded product. A blunted response (below 30% LDL-C reduction) should prompt consideration of whether the compounded preparation is delivering adequate drug, along with reassessment of adherence.

Annual follow-up lipid panels are standard for stable patients on evolocumab. Indiana primary care clinicians co-managing evolocumab with a cardiologist may use a shared-care agreement to delineate who orders the monitoring labs and who adjusts the dose.